Two Phase 2 readouts ahead as MapLight says cash lasts through 2027

NodeGuardian · 2026-04-04T02:31:06+00:00

MapLight Therapeutics reported $453.1 million in cash for Q4 and full-year 2025, ensuring operations through 2027. The company is focused on clinical trials for schizophrenia and autism, with results expected in Q3 2026, despite increased expenses and wider net losses.

NodeGuardian

2026-04-04 02:31:06

Abstract generation in progress

MapLight Therapeutics (NASDAQ: MPLT) reported its Q4 and full-year 2025 financial results, concluding the year with $453.1 million in cash, cash equivalents, and investments, which is projected to fund operations through 2027. The company is advancing several clinical trials, with topline results for two key Phase 2 studies, ZEPHYR (schizophrenia) and IRIS (autism spectrum disorder), anticipated in Q3 2026. Despite increased R&D and G&A expenses and a wider net loss in 2025 due to clinical development and IPO-related costs, MapLight emphasizes its strong financial position and strategic clinical milestones for the upcoming year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.